Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Autosomal thrombocytopenia with normal platelets
Autosomal thrombocytopenia with normal platelets
Autosomal thrombocytopenia with normal platelets
Drug discovery
28
papers
On emerging therapies
Rare hematologic diseases
Autosomal thrombocytopenia with normal platelets
Overview
Autosomal thrombocytopenia with normal platelets is a rare inherited disorder characterized by low platelet count (typically 50-150 × 10³/µL) despite normal platelet size and function. It often presents with mild bleeding tendencies (e.g., easy bruising), though severe hemorrhage is uncommon. Diagnosis requires genetic testing to identify pathogenic variants in genes like ANKRD26 or ETV6, which affect megakaryocyte maturation without altering platelet morphology.
Therapies
Categories: rare genetic diseases, rare hematological diseases
Research Papers
28 drug discovery papers about Autosomal thrombocytopenia with normal platelets. Recent publications:
28 drug discovery papers about Autosomal thrombocytopenia with normal platelets. Recent publications:
categories:
Small molecules
small molecules
2026-02-12 | Autosomal dominant thrombocytopenia associated with the CYCS p.Arg92Gly variant: clinical characterization of an additional family and observation of antiplatelet tolerance.
Thrombocytopenia 4 (THC4) is a rare autosomal dominant inherited thrombocytopenia caused by pathogenic variants in CYCS, the gene encoding cytochrome c. Although CYCS-related thrombocytopenia is well characterized as a mild, non-syndromic quantitative platelet disorder, few families have been described worldwide. Recently, the missense variant c.274A > G (p.Arg92Gly) was reported in a single family. Here, we describe an additional multi-generational family from the Middle East carrying the same variant, thereby providing independent confirmation of pathogenicity and expanding the available phenotypic data. Seven affected individuals exhibited stable, moderate thrombocytopenia (55-88 × 109/L) with normal platelet size and morphology, normal platelet aggregation responses, and no syndromic features. One newborn presented with petechiae and grade 1 intracranial hemorrhage but recovered fully. Whole-exome sequencing identified p.Arg92Gly as the only variant segregating with disease; Sanger sequencing confirmed heterozygosity in all affected members. Structural modeling demonstrated loss of stabilizing hydrogen bonds involving a highly conserved residue within the C-terminal helical region of cytochrome c, likely impairing local structural stability. Importantly, one affected individual tolerated long-term aspirin and clopidogrel therapy following an ischemic stroke without bleeding complications-an observation not previously reported in THC4. This Brief Report strengthens the association between CYCS p.Arg92Gly and inherited thrombocytopenia and provides clinically important data regarding antiplatelet therapy safety in this rare condition.
2025-11-03 | First report: A novel deep intronic mutation and treatment using hetrombopag olamine of a patient with MYH9 syndrome and immune thrombocytopenia
Abstract Introduction: MYH9-related diseases (MYH9-RD), caused by pathogenic variants in the MYH9 gene through an autosomal dominant inheritance pattern, are characterized by congenital thrombocytopenia, giant platelets, and Döhle-like inclusions in neutrophils, with variable features such as sensorineural hearing loss, cataracts, and nephropathy. Giant platelet thrombocytopenia, which is one of the most remarkable manifestations of MYH9 syndrome, remains poorly understood in terms of its mechanisms, and there are no unified treatment recommendations. The incidence of thrombocytopenia caused by MYH9 mutations is also not well established. Therefore, we conducted this study to shed light on potential treatment strategies. Here, we report the first documented case of MYH9-RD caused by a novel deep intronic mutation. The associated refractory thrombocytopenia was successfully managed with the thrombopoietin receptor agonist hetrombopag olamine, expanding both the genetic and therapeutic landscape of this rare disorder. Methods: A 22-year-old male with lifelong refractory thrombocytopenia was enrolled. Detailed clinical history and physical examination were reviewed, followed by routine laboratory investigations, including blood counts, peripheral smear, bone marrow cytology, and autoimmune workup, to exclude other causes and support a working diagnosis of immune thrombocytopenia. Whole-exome sequencing (WES) was conducted on the proband and his parents. A minigene splicing assay using pcMINI/pcMINI-N vectors was performed in HEK-293T and HeLa cells to evaluate splicing impact. Patient and maternal peripheral blood RNA were analyzed via nested RT-PCR, TA cloning, and Sanger sequencing. Structural modeling was used to visualize protein changes. Results: He had a baseline platelet count of 11×10⁹/L and recurrent mucocutaneous bleeding. He had been misdiagnosed with ITP for over a decade, showing poor response to steroids, eltrombopag, and rhTPO. Examination of peripheral blood smear revealed giant platelets and Döhle-like inclusions. The patient's laboratory tests revealed immune thrombocytopenia. WES identified a heterozygous deep intronic mutation c.2977-75C>T in MYH9, absent in population databases (gnomAD v4.1.1, ClinVar). The variant was maternally inherited (mother asymptomatic), and classified as a variant of uncertain significance (PM2_Supporting + PP3 per ACMG/AMP guidelines).Functional studies revealed that the mutation disrupted normal splicing, producing two aberrant transcripts: (1) a 138-bp intronic insertion leading to a truncated protein (p.Lys994_Glu1960delinsAsnProAsnGluLeuAspGlnAlaSerLysAlaLeuSerIleGlnProGlnIleSerGly; 1013 aa), and (2) a 62-bp retention leading to a frameshift and premature termination (p.Lys994AsnfsTer29; 1021 aa). Both abnormal isoforms lacked the C-terminal tail of NMMHC-IIA, critical for dimerization and cytoskeletal function. Hetrombopag olamine (5 mg daily) was initiated in August 2024. Platelet count rose from 22×10⁹/L at baseline to 34×10⁹/L at week 2, peaked at 92×10⁹/L at 1 month, and stabilized between 38–42×10⁹/L post-discontinuation. No adverse effects were observed during or after treatment. Conclusion: This is the first report of MYH9-RD caused by a deep intronic c.2977-75C>T mutation, which induces exonization and protein truncation. The positive clinical response to hetrombopag olamine demonstrates its therapeutic potential in MYH9-RD. Our findings support the inclusion of deep intronic variants in diagnostic pipelines and suggest TPO-RAs as a promising therapeutic approach in such cases.
2024-04-24 | Enigmatic missense mutations can cause disease via creation of de novo nuclear export signals.
Summary Disease-causing missense mutations that occur within structurally and functionally unannotated protein regions can guide researchers to new mechanisms of protein regulation and dysfunction. Here, we report that the thrombocytopenia-, myelodysplastic syndromes-, and leukemia-associated P214L mutation in the transcriptional regulator ETV6 creates an XPO1-dependent nuclear export signal to cause protein mislocalization. Strategies to disrupt XPO1 activity fully restore ETV6 P214L protein nuclear localization and transcription regulation activity. Mechanistic insight inspired the design of a ‘humanized’ ETV6 mice, which we employ to demonstrate that the germline P214L mutation is sufficient to elicit severe defects in thrombopoiesis and hematopoietic stem cell maintenance. Beyond ETV6, we employed computational methods to uncover rare disease-associated missense mutations in unrelated proteins that create a nuclear export signal to disrupt protein function. Thus, missense mutations that operate through this mechanism should be predictable and may suggest rational therapeutic strategies for associated diseases.
2023-10-30 | Analysis of clinical characteristics and treatment efficacy in two pediatric cases of ANKRD26-related thrombocytopenia.
ANKRD26-related thrombocytopenia (ANKRD26-RT or THC2, MIM 188 000), an autosomal dominant thrombocytopenia, is unresponsive to immunosuppressive therapy and susceptible to hematological malignancies. A large number of pediatric patients are diagnosed with immune thrombocytopenia (ITP) every year; however, thrombocytopenia of genetic origin is often missed. Extensive characterization of ANKRD26-RT will help prevent missed diagnosis and misdiagnosis. Furthermore, identification of ANKRD26-RT will help in the formulation of an accurate diagnosis and a treatment plan. In our study, we report cases of two Chinese pediatric patients with ANKRD26-RT and analyze their clinical characteristics, gene mutations, and treatment modalities. Both patients were 1-year-old and presented with mild bleeding (World Health Organization(WHO) score grade 1), different degrees of platelet reduction, normal mean platelet volume, and megakaryocyte maturation impairment not obvious. Genetic tests revealed that both patients had ANKRD26 gene mutations.Patient 1 had a mutation c.-140C>G of the 5' untranslated region (UTR), and patient 2 had a mutation of c.-127A>T of 5'UTR. Both patients were treated with eltrombopag, and the treatment was no response, with no adverse reactions. What is the background? ANKRD26-RT is an autosomal dominant thrombocytopenia which is unresponsive to immunosuppressive therapy and susceptible to hematological malignancies.It is rare and lacks specific clinical features, making misdiagnosis easy.Some studies report that eltrombopag is safe and effective for short-term treatment of the disease; however, these reports are limited.What we did and summary of findings. We retrospectively studied the clinical manifestations and diagnosis process of ANKRD26-RT and discussed the treatment efficacy of immunosuppressants and eltrombopag for its management.We found two pediatric cases of patients with ANKRD26-RT with varying degrees of thrombocytopenia, mild bleeding, normal mean platelet volume, and megakaryocyte maturation impairment that was not obvious. Immunosuppressant treatment wasunresponsiveor temporarily responsivebut not sustained , and short-term administration of eltrombopag (25 mg/day) was safe, but it did not effectively improve the patients’ platelet counts.What is the impact? If patients clinically diagnosed with immune thrombocytopenia do not respond to immunosuppressive agents, genetic testing should be conducted to exclude hereditary thrombocytopenia, and a normal mean platelet volume should not exclude the possibility of the disease.For patients with ANKRD26-RT, eltrombopag is safe for short-term use;however, 25 mg/day treatment is unresponsive.Ourreport complements data on the diagnosis and management of ANKRD26-RT disease in children.
2023-05-12 | Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3
Megakaryocytes (MKs) are the precursor cells of platelets, located in the bone marrow (BM). Once mature, they extend elongated projections named proplatelets through sinusoid vessels, emerging from the marrow stroma into the circulating blood. Not all signals from the microenvironment that regulate proplatelet formation are understood, particularly those from the BM biomechanics. We sought to investigate how MKs perceive and adapt to modifications of the stiffness of their environment. Although the BM is one of the softest tissue of the body, its rigidification results from excess fibronectin (FN), and other matrix protein deposition occur upon myelofibrosis. Here, we have shown that mouse MKs are able to detect the stiffness of a FN-coated substrate and adapt their morphology accordingly. Using a polydimethylsiloxane substrate with stiffness varying from physiological to pathological marrow, we found that a stiff matrix favors spreading, intracellular contractility, and FN fibrils assembly at the expense of proplatelet formation. Itgb3, but not Itgb1, is required for stiffness sensing, whereas both integrins are involved in fibrils assembly. In contrast, soft substrates promote proplatelet formation in an Itgb3-dependent manner, consistent with the ex vivo decrease in proplatelet formation and the in vivo decrease in platelet number in Itgb3-deficient mice. Our findings demonstrate the importance of environmental stiffness for MK functions with potential pathophysiological implications during pathologies that deregulate FN deposition and modulate stiffness in the marrow.
antibodies
2023-06-22 | NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells
Loss of NBEAL2 function leads to grey platelet syndrome (GPS), a bleeding disorder characterized by macro-thrombocytopenia and α-granule-deficient platelets. A proportion of patients with GPS develop autoimmunity through an unknown mechanism, which might be related to the proteins NBEAL2 interacts with, specifically in immune cells. Here we show a comprehensive interactome of NBEAL2 in primary T cells, based on mass spectrometry identification of altogether 74 protein association partners. These include LRBA, a member of the same BEACH domain family as NBEAL2, recessive mutations of which cause autoimmunity and lymphocytic infiltration through defective CTLA-4 trafficking. Investigating the potential association between NBEAL2 and CTLA-4 signalling suggested by the mass spectrometry results, we confirm by co-immunoprecipitation that CTLA-4 and NBEAL2 interact with each other. Interestingly, NBEAL2 deficiency leads to low CTLA-4 expression in patient-derived effector T cells, while their regulatory T cells appear unaffected. Knocking-down NBEAL2 in healthy primary T cells recapitulates the low CTLA-4 expression observed in the T cells of GPS patients. Our results thus show that NBEAL2 is involved in the regulation of CTLA-4 expression in conventional T cells and provide a rationale for considering CTLA-4-immunoglobulin therapy in patients with GPS and autoimmune disease.
small molecules
2026-02-12 | Autosomal dominant thrombocytopenia associated with the CYCS p.Arg92Gly variant: clinical characterization of an additional family and observation of antiplatelet tolerance.
Thrombocytopenia 4 (THC4) is a rare autosomal dominant inherited thrombocytopenia caused by pathogenic variants in CYCS, the gene encoding cytochrome c. Although CYCS-related thrombocytopenia is well characterized as a mild, non-syndromic quantitative platelet disorder, few families have been described worldwide. Recently, the missense variant c.274A > G (p.Arg92Gly) was reported in a single family. Here, we describe an additional multi-generational family from the Middle East carrying the same variant, thereby providing independent confirmation of pathogenicity and expanding the available phenotypic data. Seven affected individuals exhibited stable, moderate thrombocytopenia (55-88 × 109/L) with normal platelet size and morphology, normal platelet aggregation responses, and no syndromic features. One newborn presented with petechiae and grade 1 intracranial hemorrhage but recovered fully. Whole-exome sequencing identified p.Arg92Gly as the only variant segregating with disease; Sanger sequencing confirmed heterozygosity in all affected members. Structural modeling demonstrated loss of stabilizing hydrogen bonds involving a highly conserved residue within the C-terminal helical region of cytochrome c, likely impairing local structural stability. Importantly, one affected individual tolerated long-term aspirin and clopidogrel therapy following an ischemic stroke without bleeding complications-an observation not previously reported in THC4. This Brief Report strengthens the association between CYCS p.Arg92Gly and inherited thrombocytopenia and provides clinically important data regarding antiplatelet therapy safety in this rare condition.
2025-11-03 | First report: A novel deep intronic mutation and treatment using hetrombopag olamine of a patient with MYH9 syndrome and immune thrombocytopenia
Abstract Introduction: MYH9-related diseases (MYH9-RD), caused by pathogenic variants in the MYH9 gene through an autosomal dominant inheritance pattern, are characterized by congenital thrombocytopenia, giant platelets, and Döhle-like inclusions in neutrophils, with variable features such as sensorineural hearing loss, cataracts, and nephropathy. Giant platelet thrombocytopenia, which is one of the most remarkable manifestations of MYH9 syndrome, remains poorly understood in terms of its mechanisms, and there are no unified treatment recommendations. The incidence of thrombocytopenia caused by MYH9 mutations is also not well established. Therefore, we conducted this study to shed light on potential treatment strategies. Here, we report the first documented case of MYH9-RD caused by a novel deep intronic mutation. The associated refractory thrombocytopenia was successfully managed with the thrombopoietin receptor agonist hetrombopag olamine, expanding both the genetic and therapeutic landscape of this rare disorder. Methods: A 22-year-old male with lifelong refractory thrombocytopenia was enrolled. Detailed clinical history and physical examination were reviewed, followed by routine laboratory investigations, including blood counts, peripheral smear, bone marrow cytology, and autoimmune workup, to exclude other causes and support a working diagnosis of immune thrombocytopenia. Whole-exome sequencing (WES) was conducted on the proband and his parents. A minigene splicing assay using pcMINI/pcMINI-N vectors was performed in HEK-293T and HeLa cells to evaluate splicing impact. Patient and maternal peripheral blood RNA were analyzed via nested RT-PCR, TA cloning, and Sanger sequencing. Structural modeling was used to visualize protein changes. Results: He had a baseline platelet count of 11×10⁹/L and recurrent mucocutaneous bleeding. He had been misdiagnosed with ITP for over a decade, showing poor response to steroids, eltrombopag, and rhTPO. Examination of peripheral blood smear revealed giant platelets and Döhle-like inclusions. The patient's laboratory tests revealed immune thrombocytopenia. WES identified a heterozygous deep intronic mutation c.2977-75C>T in MYH9, absent in population databases (gnomAD v4.1.1, ClinVar). The variant was maternally inherited (mother asymptomatic), and classified as a variant of uncertain significance (PM2_Supporting + PP3 per ACMG/AMP guidelines).Functional studies revealed that the mutation disrupted normal splicing, producing two aberrant transcripts: (1) a 138-bp intronic insertion leading to a truncated protein (p.Lys994_Glu1960delinsAsnProAsnGluLeuAspGlnAlaSerLysAlaLeuSerIleGlnProGlnIleSerGly; 1013 aa), and (2) a 62-bp retention leading to a frameshift and premature termination (p.Lys994AsnfsTer29; 1021 aa). Both abnormal isoforms lacked the C-terminal tail of NMMHC-IIA, critical for dimerization and cytoskeletal function. Hetrombopag olamine (5 mg daily) was initiated in August 2024. Platelet count rose from 22×10⁹/L at baseline to 34×10⁹/L at week 2, peaked at 92×10⁹/L at 1 month, and stabilized between 38–42×10⁹/L post-discontinuation. No adverse effects were observed during or after treatment. Conclusion: This is the first report of MYH9-RD caused by a deep intronic c.2977-75C>T mutation, which induces exonization and protein truncation. The positive clinical response to hetrombopag olamine demonstrates its therapeutic potential in MYH9-RD. Our findings support the inclusion of deep intronic variants in diagnostic pipelines and suggest TPO-RAs as a promising therapeutic approach in such cases.
2024-04-24 | Enigmatic missense mutations can cause disease via creation of de novo nuclear export signals.
Summary Disease-causing missense mutations that occur within structurally and functionally unannotated protein regions can guide researchers to new mechanisms of protein regulation and dysfunction. Here, we report that the thrombocytopenia-, myelodysplastic syndromes-, and leukemia-associated P214L mutation in the transcriptional regulator ETV6 creates an XPO1-dependent nuclear export signal to cause protein mislocalization. Strategies to disrupt XPO1 activity fully restore ETV6 P214L protein nuclear localization and transcription regulation activity. Mechanistic insight inspired the design of a ‘humanized’ ETV6 mice, which we employ to demonstrate that the germline P214L mutation is sufficient to elicit severe defects in thrombopoiesis and hematopoietic stem cell maintenance. Beyond ETV6, we employed computational methods to uncover rare disease-associated missense mutations in unrelated proteins that create a nuclear export signal to disrupt protein function. Thus, missense mutations that operate through this mechanism should be predictable and may suggest rational therapeutic strategies for associated diseases.
2023-10-30 | Analysis of clinical characteristics and treatment efficacy in two pediatric cases of ANKRD26-related thrombocytopenia.
ANKRD26-related thrombocytopenia (ANKRD26-RT or THC2, MIM 188 000), an autosomal dominant thrombocytopenia, is unresponsive to immunosuppressive therapy and susceptible to hematological malignancies. A large number of pediatric patients are diagnosed with immune thrombocytopenia (ITP) every year; however, thrombocytopenia of genetic origin is often missed. Extensive characterization of ANKRD26-RT will help prevent missed diagnosis and misdiagnosis. Furthermore, identification of ANKRD26-RT will help in the formulation of an accurate diagnosis and a treatment plan. In our study, we report cases of two Chinese pediatric patients with ANKRD26-RT and analyze their clinical characteristics, gene mutations, and treatment modalities. Both patients were 1-year-old and presented with mild bleeding (World Health Organization(WHO) score grade 1), different degrees of platelet reduction, normal mean platelet volume, and megakaryocyte maturation impairment not obvious. Genetic tests revealed that both patients had ANKRD26 gene mutations.Patient 1 had a mutation c.-140C>G of the 5' untranslated region (UTR), and patient 2 had a mutation of c.-127A>T of 5'UTR. Both patients were treated with eltrombopag, and the treatment was no response, with no adverse reactions. What is the background? ANKRD26-RT is an autosomal dominant thrombocytopenia which is unresponsive to immunosuppressive therapy and susceptible to hematological malignancies.It is rare and lacks specific clinical features, making misdiagnosis easy.Some studies report that eltrombopag is safe and effective for short-term treatment of the disease; however, these reports are limited.What we did and summary of findings. We retrospectively studied the clinical manifestations and diagnosis process of ANKRD26-RT and discussed the treatment efficacy of immunosuppressants and eltrombopag for its management.We found two pediatric cases of patients with ANKRD26-RT with varying degrees of thrombocytopenia, mild bleeding, normal mean platelet volume, and megakaryocyte maturation impairment that was not obvious. Immunosuppressant treatment wasunresponsiveor temporarily responsivebut not sustained , and short-term administration of eltrombopag (25 mg/day) was safe, but it did not effectively improve the patients’ platelet counts.What is the impact? If patients clinically diagnosed with immune thrombocytopenia do not respond to immunosuppressive agents, genetic testing should be conducted to exclude hereditary thrombocytopenia, and a normal mean platelet volume should not exclude the possibility of the disease.For patients with ANKRD26-RT, eltrombopag is safe for short-term use;however, 25 mg/day treatment is unresponsive.Ourreport complements data on the diagnosis and management of ANKRD26-RT disease in children.
2023-05-12 | Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3
Megakaryocytes (MKs) are the precursor cells of platelets, located in the bone marrow (BM). Once mature, they extend elongated projections named proplatelets through sinusoid vessels, emerging from the marrow stroma into the circulating blood. Not all signals from the microenvironment that regulate proplatelet formation are understood, particularly those from the BM biomechanics. We sought to investigate how MKs perceive and adapt to modifications of the stiffness of their environment. Although the BM is one of the softest tissue of the body, its rigidification results from excess fibronectin (FN), and other matrix protein deposition occur upon myelofibrosis. Here, we have shown that mouse MKs are able to detect the stiffness of a FN-coated substrate and adapt their morphology accordingly. Using a polydimethylsiloxane substrate with stiffness varying from physiological to pathological marrow, we found that a stiff matrix favors spreading, intracellular contractility, and FN fibrils assembly at the expense of proplatelet formation. Itgb3, but not Itgb1, is required for stiffness sensing, whereas both integrins are involved in fibrils assembly. In contrast, soft substrates promote proplatelet formation in an Itgb3-dependent manner, consistent with the ex vivo decrease in proplatelet formation and the in vivo decrease in platelet number in Itgb3-deficient mice. Our findings demonstrate the importance of environmental stiffness for MK functions with potential pathophysiological implications during pathologies that deregulate FN deposition and modulate stiffness in the marrow.
antibodies
2023-06-22 | NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells
Loss of NBEAL2 function leads to grey platelet syndrome (GPS), a bleeding disorder characterized by macro-thrombocytopenia and α-granule-deficient platelets. A proportion of patients with GPS develop autoimmunity through an unknown mechanism, which might be related to the proteins NBEAL2 interacts with, specifically in immune cells. Here we show a comprehensive interactome of NBEAL2 in primary T cells, based on mass spectrometry identification of altogether 74 protein association partners. These include LRBA, a member of the same BEACH domain family as NBEAL2, recessive mutations of which cause autoimmunity and lymphocytic infiltration through defective CTLA-4 trafficking. Investigating the potential association between NBEAL2 and CTLA-4 signalling suggested by the mass spectrometry results, we confirm by co-immunoprecipitation that CTLA-4 and NBEAL2 interact with each other. Interestingly, NBEAL2 deficiency leads to low CTLA-4 expression in patient-derived effector T cells, while their regulatory T cells appear unaffected. Knocking-down NBEAL2 in healthy primary T cells recapitulates the low CTLA-4 expression observed in the T cells of GPS patients. Our results thus show that NBEAL2 is involved in the regulation of CTLA-4 expression in conventional T cells and provide a rationale for considering CTLA-4-immunoglobulin therapy in patients with GPS and autoimmune disease.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.